Legal & General Group
BXRX

Legal & General Group’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Legal & General Group’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed -$4K – 3506
2020
Q1 		$4K Hold
1
– – ﹤0.01% 3298
2019
Q4 		$11K Buy
+1
New +$8.53K ﹤0.01% 3288

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Legal & General Group's BXRX Position: Q2 2020 in Review

Legal & General Group sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2020, closing a stake of 1 share — an estimated $4K sold.

Legal & General Group first reported a position in BXRX in Q4 2019 and held it in 2 quarters. The position peaked at $11K in Q4 2019. 38 funds tracked by Wall St. Rank hold BXRX as of Q2 2020.

  • Legal & General Group reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Legal & General Group sold 1 Baudax Bio, Inc. Common Stock share in Q2 2020, an estimated $4K.
  • Legal & General Group first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Legal & General Group's Baudax Bio, Inc. Common Stock position peaked at $11K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2020.

Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.